In the quiet corners of our local markets, tucked among bags of dried barks, aromatic leaves, and citrus fruits, lies a sophisticated pharmacological toolkit often overlooked for synthetic ...

In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Monte Rosa Therapeutics (NASDAQ:GLUE) stock surged 13% after the company reported positive interim Phase 1 data for its MRT-8102 drug, demonstrating significant r ...